Referências: 1. Giancane G, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO). Treatment of juvenile idiopathic arthritis: what’s new? Curr Opin Rheumatol. 2019 Sep;31(5):428-435. doi: 10.1097/ BOR.0000000000000632. PMID: 31169547 2. Relatório de recomendação. PCDT Artrite Idiopática Juvenil (AIJ) agosto/2021. 3. Tofacitinib for treating juvenile idiopathic arthritis.: 20 October 2021 www.nice.org.uk/guidance/ta735 4. CDR CLINICAL REVIEW REPORT FOR ACTEMRA. Clinical Review Report. August 2014. Canadian Agency for Drugs and Technologies in Health (CADTH) 5. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis & Rheumatology Vol. 0, No. 0, Month 2022, pp 1–17 DOI 10.1002/art.42037 44
RkJQdWJsaXNoZXIy MjcxMg==